2. Membrane Transporter/Ion Channel Neuronal Signaling GPCR/G Protein Autophagy Immunology/Inflammation
  3. TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE)
  4. EIPA

EIPA  (Synonyms: L593754; MH 12-43; Ethylisopropylamiloride)

Cat. No.: HY-101840 Purity: 99.73%
COA Handling Instructions

EIPA (L593754) est un inhibiteur de canal TRPP3 avec un IC50 de 10,5 μM. EIPA inhibe également les échangeurs Na+/H+ (NHE) et macropinocytose.

EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.

For research use only. We do not sell to patients.

EIPA Chemical Structure

EIPA Chemical Structure

CAS No. : 1154-25-2

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 55 In-stock
Solid
5 mg USD 50 In-stock
10 mg USD 80 In-stock
50 mg USD 280 In-stock
100 mg USD 450 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 36 publication(s) in Google Scholar

Other Forms of EIPA:

EIPA Related Antibodies

Top Publications Citing Use of Products

36 Publications Citing Use of MCE EIPA

View All TRP Channel Isoform Specific Products:

View All Isoforms
TRPC TRPM TRPV TRPA TRPML

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma[1][2][3][5].

IC50 & Target[7]

COX-2

 

In Vitro

EIPA (100 μM, 30 min) suppresses TRPP3-mediated Ca2+ uptake in X. laevis oocytes[1].
? EIPA hydrochloride (10-100 μM) reversibly inhibits the basal Na+ current (IC50: 19.5 μM)[1].
? EIPA (300 μM, 6h) enhances autophagy through NHE3 (Na+/H+-exchanger 3) in IEC-18 cells[2].
? EIPA (20 μM, 2 h) blocks macropinocytosis-mediated uptake of CA-PZ massively entry in HT-29 cells and MIA PaCa-2 cells[3].
? EIPA (30 μM, 3h) attenuates Zinc/Kainate toxicity by decreasing Zn2+ entry in cerebellar granule neurons[4].
? EIPA (5-100 μM, 48h) suppresses proliferation of MKN28 cells through up-regulation of p21 expression[5].
? EIPA (3 μM, 6 h) inhibits the LPS-induced increase in the level of COX-2 protein[7].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

EIPA Related Antibodies

Cell Proliferation Assay[5]

Cell Line: MKN28 cells
Concentration: 5, 10, 25, 50, and 100 μM
Incubation Time: 48 h
Result: Inhibited cell proliferation in a dose- and time-dependent manner.

Western Blot Analysis[2]

Cell Line: IEC-18 cells
Concentration: 300 μM
Incubation Time: 6 h
Result: Increased total LC3-II protein levels and P62 flux.
Increased ATG5, 7, 12 and P62 expression.
In Vivo

EIPA (Intravenous injection, 1 mg/kg) dose-dependently attenuates the I/R (Ischemia/reperfusion)-induced renal dysfunction in ddY strain mice[6].
? EIPA (oral administration, 10 mg/kg) inhibits LPS-induced inflammation in air pouch-type LPS-induced inflammation model[7].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male ddY strain mice[6]
Dosage: 1 mg/kg
Administration: Intravenous injection
Result: Attenuated histologic renal damage, and imprved the I/R-induced increases in renal ET-1 contents.
Animal Model: Air pouch-type LPS-induced inflammation model[7]
Dosage: 10 mg/kg
Administration: Oral administration
Result: Inhibited the LPS-induced infiltration of leukocytes into the pouch.
Inhibited the amount of PGE2 in the pouch fluid.
Molecular Weight

299.76

Appearance

Solid

Formula

C11H18ClN7O
CAS No.
SMILES

O=C(C1=NC(Cl)=C(N(CC)C(C)C)N=C1N)NC(N)=N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (166.80 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (ultrasonic) (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3360 mL 16.6800 mL 33.3600 mL
5 mM 0.6672 mL 3.3360 mL 6.6720 mL
10 mM 0.3336 mL 1.6680 mL 3.3360 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.34 mM); Clear solution

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 99.73%

COA (247 KB) LCMS (407 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

EIPA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

EIPA1154-25-2L593754 MH 12-43 EthylisopropylamilorideL 593754L-593754TRP ChannelProstaglandin ReceptorAutophagyCOXNa+/H+ Exchanger (NHE)Transient receptor potential channelsCyclooxygenaseSodium/hydrogen ExchangerSodium-hydrogen ExchangerCation channelNHE3IECsIBDsIEC-18neuronzinccalciumkainiteMKN28gastric cancercolon carcinomapancreatic carcinomarenal failureddY strain miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
EIPA
Cat. No.:
HY-101840
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.